Visceral Sensitivity in IBD and IBS: Role of Inflammation, Immune Activity and Genetic Factors
Aim: More insight in pathogenesis of IBS and IBD. Samples are collected in context of an European research project.
⁃ For group 1: IBS
• Irritable Bowel Syndrome (IBS) (ROME III criteria)
• No obvious organic explanation for the IBS symptoms
• Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study
⁃ Group 2: active ulcerative colitis 1. diagnosis of ulcerative colitis (Confirmed by at least one sigmoidoscopy) 3. Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study
⁃ Group 3: ulcerative colitis in remission (3a: with IBS symptoms, 3b: without IBS symptoms)
• diagnosis of ulcerative colitis (Confirmed by at least one sigmoidoscopy)
• remission is confirmed by at least one sigmoidoscopy
• Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study
• Only for group 3a:
• Rome III criteria for IBS
⁃ Group 4: Healthy controls No abdominal (pain) complaints.
⁃ Group 5: active Crohn's disease
⁃ 1\. diagnosis of Crohn's disease (Confirmed by at least one sigmoidoscopy) 3. Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study
⁃ Group 6: Crohn's disease in remission (6a: with IBS symptoms, 6b: without IBS symptoms)
• diagnosis of Crohn's disease (Confirmed by at least one sigmoidoscopy)
• remission is confirmed by at least one sigmoidoscopy
• Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study